Mulmit

Fulcrum Therapeutics, Inc.Fulcrum Therapeutics, Inc.

FULC Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-310-84,769,000-74,880,000-1.18
2024-12-3180,000,000-21,897,000-9,725,000-0.16
2023-12-312,805,000-110,664,000-97,340,000-1.59
2022-12-316,342,000-112,561,000-109,871,000-2.44
2021-12-3119,163,000-81,054,000-80,847,000-2.29

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-07-17TANG KEVIN50,945
2026-07-16TANG KEVIN116,671
2026-07-15TANG KEVIN107,377
2026-07-14TANG KEVIN53,651
2026-07-14TANG KEVIN75,952
2026-07-13TANG KEVIN12,966
2026-06-30Banks Sonja32,000
2026-06-30Dorton Katina32,000
2026-06-30Gould Robert J32,000
2026-06-30Haviland Kate32,000
2026-06-30King Rachel K.32,000
2026-06-30GERAGHTY JAMES A32,000

8-K events

FiledItems
2026-08-17Entry into a material agreement · Unregistered sales of equity securities · Change in control · Officer or director change · Regulation FD disclosure · Financial statements and exhibits
2026-08-10Officer or director change
2026-06-25Submission of matters to a vote
2026-06-11Officer or director change
2026-06-04Costs associated with exit or disposal activities · Other events
2026-06-01Other events · Financial statements and exhibits
2026-04-27Termination of a material agreement · Results of operations · Officer or director change · Financial statements and exhibits
2026-02-24Results of operations · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Pharmaceutical Preparations — 같은 업종, 그리고 규모가 비슷한 기업Pharmaceutical Preparations — and other companies of a similar size

SEC가 같은 업종(Pharmaceutical Preparations)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Pharmaceutical Preparations) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.